• CoMO

GSK and Pfizer Complete Transaction of Meningitis Assets Mencevax and Nimenrix

05 October 2015

GlaxoSmithKline (GSK) and Pfizer have successfully completed the transfer of GSK’s meningitis vaccines Nimenrix® (Meningococcal serogroups A, C, W-135 and Y conjugate vaccine) and Mencevax® (Meningococcal serogroups A, C, W-135 and Y polysaccharide vaccine) which were acquired by Pfizer Ireland Pharmaceuticals (a subsidiary of Pfizer Inc), effective 1 October 2015.

GSK’s divestment of these vaccines is required in order to satisfy regulatory clearances as part of their three-part transaction with Novartis AG, completed in March this year. With this transaction, GSK acquired Novartis’ global vaccines business (excluding influenza vaccines) including the meningitis vaccines Menveo (Meningococcal serogroups A, C, W-135 and Y conjugate vaccine) and Bexsero (Meningococcal serogroup B vaccine).

Effective from 1 October 2015, Pfizer is responsible for the marketing and promotion of these vaccines. 

For a transition period following 1 October 2015, GSK shall continue to manage all pharmacovigilance activities, medical information inquiries and any product complaints. GSK will also continue managing orders and distribution during this transition period.

If you have a medical enquiry, please contact GSK medical information on 1800 033 109 or MEL.Australia-Medinfo@gsk.com

For more information please contact:

Samantha Rosoman, Admin and Marketing Officer

E: samanthar@meningitis.org


Recent Posts

See All
  • Facebook Social Icon
  • Twitter Social Icon
  • YouTube
  • Instagram Social Icon

Copyright © 2020 CoMO |  Privacy Accessibility  |  Disclaimer  |  

Follow us for regular updates about meningitis worldwide.

A charity registered in England and Wales no. 1167023